Medication Summary

Corticosteroid therapy is useful in treating some patients with drug-induced lung toxicity, but results can vary. Generally, most patients require inpatient, as well as outpatient, corticosteroid therapy.

Before starting any medication, patients should be educated about the potential adverse effects of the drug. Patients who develop drug toxicity should be advised to avoid the drug in the future.

Class Summary

Corticosteroids have anti-inflammatory properties and cause profound and varied metabolic effects. Corticosteroids modify the body's immune response to diverse stimuli and minimize activity of inflammatory cells. They are used for disease modulation and symptomatic improvement.

Prednisone (Rayos)

View full drug information

An immunosuppressant used in the treatment of autoimmune disorders, prednisone has anti-inflammatory properties and produces both glucocorticoid and mineralocorticoid effects. Therapy is best prescribed in consultation with a pulmonary disease specialist. No rigorous prospective trials have been performed in patients presenting with drug-induced lung toxicity.

Irey NS. Teaching monograph. Tissue reactions to drugs. Am J Pathol. 1976 Mar. 82 (3):613-47. [QxMD MEDLINE Link]. [Full Text].
Tamura M, Saraya T, Fujiwara M, et al. High-resolution computed tomography findings for patients with drug-induced pulmonary toxicity, with special reference to hypersensitivity pneumonitis-like patterns in gemcitabine-induced cases. Oncologist. 2013. 18 (4):454-9. [QxMD MEDLINE Link].
Todd NW, Peters WP, Ost AH, Roggli VL, Piantadosi CA. Pulmonary drug toxicity in patients with primary breast cancer treated with high-dose combination chemotherapy and autologous bone marrow transplantation. Am Rev Respir Dis. 1993 May. 147 (5):1264-70. [QxMD MEDLINE Link].
De Vuyst P, Pfitzenmeyer P, Camus P. Asbestos, ergot drugs and the pleura. Eur Respir J. 1997 Dec. 10 (12):2695-8. [QxMD MEDLINE Link].
Hillerdal G, Lee J, Blomkvist A, et al. Pleural disease during treatment with bromocriptine in patients previously exposed to asbestos. Eur Respir J. 1997 Dec. 10 (12):2711-5. [QxMD MEDLINE Link].
Schwaiblmair M, Behr W, Haeckel T, Markl B, Foerg W, Berghaus T. Drug induced interstitial lung disease. Open Respir Med J. 2012. 6:63-74. [QxMD MEDLINE Link]. [Full Text].
Drent M, Wijnen P, Bast A. Interstitial lung damage due to cocaine abuse: pathogenesis, pharmacogenomics and therapy. Curr Med Chem. 2012. 19 (33):5607-11. [QxMD MEDLINE Link].
Vandenplas O, Hantson P, Dive A, Mahieu P. Fulminant pulmonary edema following intravenous administration of radiocontrast media. Acta Clin Belg. 1990. 45 (5):334-9. [QxMD MEDLINE Link].
Vessey MP, Doll R. Investigation of relation between use of oral contraceptives and thromboembolic disease. A further report. Br Med J. 1969 Jun 14. 2 (5658):651-7. [QxMD MEDLINE Link].
Sartwell PE, Masi AT, Arthes FG, Greene GR, Smith HE. Thromboembolism and oral contraceptives: an epidemiologic case-control study. Am J Epidemiol. 1969 Nov. 90 (5):365-80. [QxMD MEDLINE Link].
Montani D, Seferian A, Savale L, Simonneau G, Humbert M. Drug-induced pulmonary arterial hypertension: a recent outbreak. Eur Respir Rev. 2013 Sep 1. 22 (129):244-50. [QxMD MEDLINE Link]. [Full Text].
Schwarz MI, Fontenot AP. Drug-induced diffuse alveolar hemorrhage syndromes and vasculitis. Clin Chest Med. 2004 Mar. 25 (1):133-40. [QxMD MEDLINE Link].
Gingo MR, George MP, Kessinger CJ, et al. Pulmonary function abnormalities in HIV-infected patients during the current antiretroviral therapy era. Am J Respir Crit Care Med. 2010 Sep 15. 182 (6):790-6. [QxMD MEDLINE Link]. [Full Text].
Toledo CH, Ross WE, Hood CI, Block ER. Potentiation of bleomycin toxicity by oxygen. Cancer Treat Rep. 1982 Feb. 66 (2):359-62. [QxMD MEDLINE Link].
Sleijfer S, van der Mark TW, Schraffordt Koops H, Mulder NH. Enhanced effects of bleomycin on pulmonary function disturbances in patients with decreased renal function due to cisplatin. Eur J Cancer. 1996 Mar. 32A (3):550-2. [QxMD MEDLINE Link].
White DA, Schwartzberg LS, Kris MG, Bosl GJ. Acute chest pain syndrome during bleomycin infusions. Cancer. 1987 May 1. 59 (9):1582-5. [QxMD MEDLINE Link].
Daba MH, El-Tahir KE, Al-Arifi MN, Gubara OA. Drug-induced pulmonary fibrosis. Saudi Med J. 2004 Jun. 25 (6):700-6. [QxMD MEDLINE Link].
Krous HF, Hamlin WB. Pulmonary toxicity due to bleomycin. Report of a case. Arch Pathol. 1973 Jun. 95 (6):407-10. [QxMD MEDLINE Link].
Kuhlman JE. The role of chest computed tomography in the diagnosis of drug-related reactions. J Thorac Imaging. 1991 Jan. 6 (1):52-61. [QxMD MEDLINE Link].
Balikian JP, Jochelson MS, Bauer KA, et al. Pulmonary complications of chemotherapy regimens containing bleomycin. AJR Am J Roentgenol. 1982 Sep. 139 (3):455-61. [QxMD MEDLINE Link].
Bellamy EA, Husband JE, Blaquiere RM, Law MR. Bleomycin-related lung damage: CT evidence. Radiology. 1985 Jul. 156 (1):155-8. [QxMD MEDLINE Link].
Santrach PJ, Askin FB, Wells RJ, Azizkhan RG, Merten DF. Nodular form of bleomycin-related pulmonary injury in patients with osteogenic sarcoma. Cancer. 1989 Aug 15. 64 (4):806-11. [QxMD MEDLINE Link].
Gehl HB, Hauptmann S, Sohn M, Bohndorf K. [Late pulmonary changes following bleomycin administration in computed tomography. Nodular fibrosis mimicking a seminoma metastasis] [German]. Radiologe. 1992 Feb. 32 (2):80-2. [QxMD MEDLINE Link].
White DA, Kris MG, Stover DE. Bronchoalveolar lavage cell populations in bleomycin lung toxicity. Thorax. 1987 Jul. 42 (7):551-2. [QxMD MEDLINE Link].
Yousem SA, Lifson JD, Colby TV. Chemotherapy-induced eosinophilic pneumonia. Relation to bleomycin. Chest. 1985 Jul. 88 (1):103-6. [QxMD MEDLINE Link].
O'Driscoll BR, Hasleton PS, Taylor PM, Poulter LW, Gattameneni HR, Woodcock AA. Active lung fibrosis up to 17 years after chemotherapy with carmustine (BCNU) in childhood. N Engl J Med. 1990 Aug 9. 323 (6):378-82. [QxMD MEDLINE Link].
Cao TM, Negrin RS, Stockerl-Goldstein KE, et al. Pulmonary toxicity syndrome in breast cancer patients undergoing BCNU-containing high-dose chemotherapy and autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2000. 6 (4):387-94. [QxMD MEDLINE Link].
Kalaycioglu M, Kavuru M, Tuason L, Bolwell B. Empiric prednisone therapy for pulmonary toxic reaction after high-dose chemotherapy containing carmustine (BCNU). Chest. 1995 Feb. 107 (2):482-7. [QxMD MEDLINE Link].
Hamada K, Nagai S, Kitaichi M, et al. Cyclophosphamide-induced late-onset lung disease. Intern Med. 2003 Jan. 42 (1):82-7. [QxMD MEDLINE Link].
Aymard JP, Gyger M, Lavallee R, Legresley LP, Desy M. A case of pulmonary alveolar proteinosis complicating chronic myelogenous leukemia. A peculiar pathologic aspect of busulfan lung?. Cancer. 1984 Feb 15. 53 (4):954-6. [QxMD MEDLINE Link].
Imokawa S, Colby TV, Leslie KO, Helmers RA. Methotrexate pneumonitis: review of the literature and histopathological findings in nine patients. Eur Respir J. 2000 Feb. 15 (2):373-81. [QxMD MEDLINE Link].
Wollner A, Mohle-Boetani J, Lambert RE, Perruquet JL, Raffin TA, McGuire JL. Pneumocystis carinii pneumonia complicating low dose methotrexate treatment for rheumatoid arthritis. Thorax. 1991 Mar. 46 (3):205-7. [QxMD MEDLINE Link].
Akoun GM, Mayaud CM, Touboul JL, Denis MF, Milleron BJ, Perrot JY. Use of bronchoalveolar lavage in the evaluation of methotrexate lung disease. Thorax. 1987 Sep. 42 (9):652-5. [QxMD MEDLINE Link].
White DA, Rankin JA, Stover DE, Gellene RA, Gupta S. Methotrexate pneumonitis. Bronchoalveolar lavage findings suggest an immunologic disorder. Am Rev Respir Dis. 1989 Jan. 139 (1):18-21. [QxMD MEDLINE Link].
Searles G, McKendry RJ. Methotrexate pneumonitis in rheumatoid arthritis: potential risk factors. Four case reports and a review of the literature. J Rheumatol. 1987 Dec. 14 (6):1164-71. [QxMD MEDLINE Link].
Beom SH, Kim DW, Sim SH, et al. Gefitinib-induced interstitial lung disease in Korean lung cancer patients. Cancer Res Treat. 2016 Jan. 48 (1):88-97. [QxMD MEDLINE Link]. [Full Text].
Hong D, Zhang G, Zhang X, Lian X. Pulmonary toxicities of gefitinib in patients with advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials. Medicine (Baltimore). 2016 Mar. 95 (9):e3008. [QxMD MEDLINE Link]. [Full Text].
Brunner AM, Costa DB, Heist RS, et al. Treatment-related toxicities in a phase II trial of dasatinib in patients with squamous cell carcinoma of the lung. J Thorac Oncol. 2013 Nov. 8 (11):1434-7. [QxMD MEDLINE Link]. [Full Text].
Dy GK, Adjei AA. Understanding, recognizing, and managing toxicities of targeted anticancer therapies. CA Cancer J Clin. 2013 Jul-Aug. 63 (4):249-79. [QxMD MEDLINE Link]. [Full Text].
Nishio M, Murakami H, Ohe Y, et al. Phase I study of TAS-121, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in patients with non-small-cell lung cancer harboring EGFR mutations. Invest New Drugs. 2019 Feb 21. [QxMD MEDLINE Link].
Tereso A, Carreto L, Baptista M, Almeida MA. Interstitial lung disease induced by crizotinib in non-small-cell lung cancer. Acta Med Port. 2019 Mar 29. 32 (3):236-9. [QxMD MEDLINE Link].
Arnon R, Raz I, Chajek-Shaul T, Berkman N, Fields S, Bar-On H. Amiodarone pulmonary toxicity presenting as a solitary lung mass. Chest. 1988 Feb. 93 (2):425-7. [QxMD MEDLINE Link].
Piccione W Jr, Faber LP, Rosenberg MS. Amiodarone-induced pulmonary mass. Ann Thorac Surg. 1989 Jun. 47 (6):918-9. [QxMD MEDLINE Link].
Sato N, Kojima K, Horio Y, et al. Successful treatment of severe amiodarone pulmonary toxicity with polymyxin B-immobilized fiber column direct hemoperfusion. Chest. 2013 Apr. 143 (4):1146-50. [QxMD MEDLINE Link].
Benassi F, Molardi A, Righi E, Santangelo R, Meli M. ECMO for pulmonary rescue in an adult with amiodarone-induced toxicity. Heart Vessels. 2015 May. 30 (3):410-5. [QxMD MEDLINE Link].
Teerakanok J, Tantrachoti P, Chariyawong P, Nugent K. Acute amiodarone pulmonary toxicity after surgical procedures. Am J Med Sci. 2016 Dec. 352 (6):646-51. [QxMD MEDLINE Link].
Gibson GR. Enalapril-induced cough. Arch Intern Med. 1989 Dec. 149 (12):2701-3. [QxMD MEDLINE Link].
Kaufman J, Casanova JE, Riendl P, Schlueter DP. Bronchial hyperreactivity and cough due to angiotensin-converting enzyme inhibitors. Chest. 1989 Mar. 95 (3):544-8. [QxMD MEDLINE Link].
Kaufman J, Schmitt S, Barnard J, Busse W. Angiotensin-converting enzyme inhibitors in patients with bronchial responsiveness and asthma. Chest. 1992 Apr. 101 (4):922-5. [QxMD MEDLINE Link].
Sebastian JL, McKinney WP, Kaufman J, Young MJ. Angiotensin-converting enzyme inhibitors and cough. Prevalence in an outpatient medical clinic population. Chest. 1991 Jan. 99 (1):36-9. [QxMD MEDLINE Link].
Kostis JB, Packer M, Black HR, Schmieder R, Henry D, Levy E. Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. Am J Hypertens. 2004 Feb. 17 (2):103-11. [QxMD MEDLINE Link].
Fisman EZ, Grossman E, Motro M, Tenenbaum A. Clinical evidence of dose-dependent interaction between aspirin and angiotensin-converting enzyme inhibitors. J Hum Hypertens. 2002 Jun. 16 (6):379-83. [QxMD MEDLINE Link].
Meune C, Mahe I, Mourad JJ, et al. Interaction between angiotensin-converting enzyme inhibitors and aspirin: a review. Eur J Clin Pharmacol. 2000 Dec. 56 (9-10):609-20. [QxMD MEDLINE Link].
Tenenbaum A, Grossman E, Shemesh J, Fisman EZ, Nosrati I, Motro M. Intermediate but not low doses of aspirin can suppress angiotensin-converting enzyme inhibitor-induced cough. Am J Hypertens. 2000 Jul. 13 (7):776-82. [QxMD MEDLINE Link].
Vleeming W, van Amsterdam JG, Stricker BH, de Wildt DJ. ACE inhibitor-induced angioedema. Incidence, prevention and management. Drug Saf. 1998 Mar. 18 (3):171-88. [QxMD MEDLINE Link].
Meeker DP, Wiedemann HP. Drug-induced bronchospasm. Clin Chest Med. 1990 Mar. 11 (1):163-75. [QxMD MEDLINE Link].
Dunn TL, Gerber MJ, Shen AS, Fernandez E, Iseman MD, Cherniack RM. The effect of topical ophthalmic instillation of timolol and betaxolol on lung function in asthmatic subjects. Am Rev Respir Dis. 1986 Feb. 133 (2):264-8. [QxMD MEDLINE Link].
Cameron RJ, Kolbe J, Wilsher ML, Lambie N. Bronchiolitis obliterans organising pneumonia associated with the use of nitrofurantoin. Thorax. 2000 Mar. 55 (3):249-51. [QxMD MEDLINE Link].
O'Donnell AE, Mappin FG, Sebo TJ, Tazelaar H. Interstitial pneumonitis associated with "crack" cocaine abuse. Chest. 1991 Oct. 100 (4):1155-7. [QxMD MEDLINE Link].
Patel RC, Dutta D, Schonfeld SA. Free-base cocaine use associated with bronchiolitis obliterans organizing pneumonia. Ann Intern Med. 1987 Aug. 107 (2):186-7. [QxMD MEDLINE Link].
Lassen CL, Zink W, Wiese CH, Graf BM, Wiesenack C. [Naloxone-induced pulmonary edema. Case report with review of the literature and critical evaluation]. Anaesthesist. 2012 Feb. 61 (2):129-36. [QxMD MEDLINE Link].
Rashdan S, Minna JD, Gerber DE. Diagnosis and management of pulmonary toxicity associated with cancer immunotherapy. Lancet Respir Med. 2018 Jun. 6 (6):472-8. [QxMD MEDLINE Link].
Franzen D, Schad K, Kowalski B, et al. Ipilimumab and early signs of pulmonary toxicity in patients with metastastic melanoma: a prospective observational study. Cancer Immunol Immunother. 2018 Jan. 67 (1):127-34. [QxMD MEDLINE Link].
Nishino M, Sholl LM, Hodi FS, Hatabu H, Ramaiya NH. Anti-PD-1-related pneumonitis during cancer immunotherapy. N Engl J Med. 2015 Jul 16. 373 (3):288-90. [QxMD MEDLINE Link]. [Full Text].
Leroy V, Templier C, Faivre JB, et al. Pembrolizumab-induced pneumonitis. ERJ Open Res. 2017 Apr. 3 (2):81. [QxMD MEDLINE Link].
Nishino M, Hatabu H, Hodi FS, Ramaiya NH. Drug-related pneumonitis in the era of precision cancer therapy. JCO Precis Oncol. 2017 May 26. [Full Text].
Montaudie H, Pradelli J, Passeron T, Lacour JP, Leroy S. Pulmonary sarcoid-like granulomatosis induced by nivolumab. Br J Dermatol. 2017 Apr. 176 (4):1060-3. [QxMD MEDLINE Link].
Gounant V, Brosseau S, Naltet C, et al. Nivolumab-induced organizing pneumonitis in a patient with lung sarcomatoid carcinoma. Lung Cancer. 2016 Sep. 99:162-5. [QxMD MEDLINE Link].
Suffredini DA, Lee JM, Peer CJ, et al. Pulmonary tumor thrombotic microangiopathy and pulmonary veno-occlusive disease in a woman with cervical cancer treated with cediranib and durvalumab. BMC Pulm Med. 2018 Jul 11. 18 (1):112. [QxMD MEDLINE Link]. [Full Text].
Khunger M, Rakshit S, Pasupuleti V, et al. Incidence of pneumonitis with use of programmed death 1 and programmed death-ligand 1 inhibitors in non-small cell lung cancer: a systematic review and meta-analysis of trials. Chest. 2017 Aug. 152 (2):271-81. [QxMD MEDLINE Link].
National Cancer Institute staff. FDA approves second CAR T-cell therapy for lymphoma. National Cancer Institute. Available at https://www.cancer.gov/news-events/cancer-currents-blog/2018/tisagenlecleucel-fda-lymphoma. May 22, 2018; Accessed: January 21, 2019.
Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998 Apr 15. 279 (15):1200-5. [QxMD MEDLINE Link].
Rosenow EC 3rd, Limper AH. Drug-induced pulmonary disease. Semin Respir Infect. 1995 Jun. 10 (2):86-95. [QxMD MEDLINE Link].
Ohri A, Arena FP. Severe pulmonary complications in African-American patient after bortezomib therapy. Am J Ther. 2006 Nov-Dec. 13 (6):553-5. [QxMD MEDLINE Link].
Pietra GG. Pathologic mechanisms of drug-induced lung disorders. J Thorac Imaging. 1991 Jan. 6 (1):1-7. [QxMD MEDLINE Link].
Kornacker M, Kraemer A, Leo E, Ho AD. Occurrence of sarcoidosis subsequent to chemotherapy for non-Hodgkin's lymphoma: report of two cases. Ann Hematol. 2002 Feb. 81 (2):103-5. [QxMD MEDLINE Link].
Chambers DC, Cherikh WS, Goldfarb SB, et al, for the International Society for Heart and Lung Transplantation. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-fifth adult lung and heart-lung transplant report-2018; focus theme: multiorgan transplantation. J Heart Lung Transplant. 2018 Oct. 37 (10):1169-83. [QxMD MEDLINE Link].
The International Society for Heart and Lung Transplantation. 2018 ISHLT adult lung transplantation statistics. Available at https://ishltregistries.org/downloadables/slides/2018/lung_overall.pptx. Accessed: April 9, 2019.
[Guideline] National Comprehensive Cancer Network (NCCN), American Society of Clinical Oncology (ASCO). Management of immunotherapy-related toxicities (immune checkpoint inhibitor-related toxicities). Version I.2018. Available at http://oncolife.com.ua/doc/nccn/immunotherapy.pdf. February 14, 2018; Accessed: January 21, 2019.
Suresh K, Naidoo J, Lin CT, Danoff S. Immune checkpoint immunotherapy for non-small cell lung cancer: benefits and pulmonary toxicities. Chest. 2018 Dec. 154 (6):1416-23. [QxMD MEDLINE Link].

Media Gallery

This image is a standard nonenhanced axial thoracic computed tomography scan. There is left lower lobe consolidation with some loss of volume and an air bronchogram. Transbronchial lung biopsy confirmed the diagnosis of cryptogenic organizing pneumonia (also known as bronchiolitis obliterans-organizing pneumonia [BOOP]).
Cryptogenic organizing pneumonia (also called bronchiolitis obliterans-organizing pneumonia [BOOP]) is often patchy and peribronchiolar. The proliferation of granulation tissue within small airways and alveolar ducts is excessive and is associated with chronic inflammation of the surrounding alveoli.
This image is a computed tomography scan of a patient with sarcoidosis. The pattern of multiple nodules seen here can manifest in patients taking medications that can cause granulomatous reactions.
This histology image from a lung biopsy specimen was obtained from the patient with sarcoidosis discussed in the previous image (see the computed tomography scan illustrating multiple nodules). Multiple areas of noncaseating granulomas are present. Drugs such as methotrexate, nitrofurantoin, procarbazine, and pentazocine can cause granulomatous lung disease.
This is a close-up histologic view of a noncaseating granuloma with a giant cell.
This histologic section of the lung shows diffuse alveolar damage in a patient with adult respiratory distress syndrome.
In usual interstitial pneumonitis or idiopathic pulmonary fibrosis, subpleural and paraseptal inflammation is present, with an appearance of temporal heterogeneity on histologic examination. Patchy scarring of the lung parenchyma and normal, or nearly normal, alveoli interspersed between fibrotic areas are the hallmarks of this disease. In addition, the lung architecture is completely destroyed.

of 7

Author

Klaus-Dieter Lessnau, MD, FCCP Former Clinical Associate Professor of Medicine, New York University School of Medicine; Medical Director, Pulmonary Physiology Laboratory, Director of Research in Pulmonary Medicine, Department of Medicine, Section of Pulmonary Medicine, Lenox Hill Hospital

Klaus-Dieter Lessnau, MD, FCCP is a member of the following medical societies: American College of Chest Physicians, American College of Physicians, American Medical Association, American Thoracic Society, Society of Critical Care Medicine

Disclosure: Nothing to disclose.

Coauthor(s)

Kevin Gerard G Lazo, DO Pulmonologist, Englewood Health Physician Network

Kevin Gerard G Lazo, DO is a member of the following medical societies: American College of Chest Physicians

Disclosure: Nothing to disclose.

Chief Editor

Zab Mosenifar, MD, FACP, FCCP Geri and Richard Brawerman Chair in Pulmonary and Critical Care Medicine, Professor and Executive Vice Chairman, Department of Medicine, Medical Director, Women's Guild Lung Institute, Cedars Sinai Medical Center, University of California, Los Angeles, David Geffen School of Medicine

Zab Mosenifar, MD, FACP, FCCP is a member of the following medical societies: American College of Chest Physicians, American College of Physicians, American Federation for Medical Research, American Thoracic Society

Disclosure: Nothing to disclose.

Additional Contributors

Ryland P Byrd, Jr, MD Professor of Medicine, Division of Pulmonary Disease and Critical Care Medicine, James H Quillen College of Medicine, East Tennessee State University

Ryland P Byrd, Jr, MD is a member of the following medical societies: American College of Chest Physicians, American Thoracic Society

Disclosure: Nothing to disclose.

Thomas M Roy, MD Chief, Division of Pulmonary Disease and Critical Care Medicine, Quillen Mountain Home Veterans Affairs Medical Center; Professor of Medicine, Division of Pulmonary Disease and Critical Care Medicine, Fellowship Program Director, James H Quillen College of Medicine, East Tennessee State University

Thomas M Roy, MD is a member of the following medical societies: American College of Chest Physicians, American College of Physicians, American Medical Association, American Thoracic Society, Southern Medical Association, Wilderness Medical Society

Disclosure: Nothing to disclose.

Acknowledgements

Arshad Ali, MD Attending Physician, Department of Pulmonary and Critical Care Medicine, Mercy General Hospital of Sacramento

Arshad Ali, MD is a member of the following medical societies: American College of Chest Physicians, American College of Physicians, and American Thoracic Society

Disclosure: Nothing to disclose. M Frances J Schmidt, MD Chief of Pulmonary Medicine, Pulmonary Fellowship Program, Teaching Attending Physician, Department of Medicine, Interfaith Medical Center

M Frances J Schmidt, MD is a member of the following medical societies: American College of Chest Physicians and American College of Physicians

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment